Ophthalmic Drug Research Articles

Cubosomes: Recent Developments and Applications from a Global Perspective

Liquid crystalline cubosomes are self-assembly of aqueous lipid and surfactant mixture. They are discrete and sub-micron in size. It is an innovative lipid-based nanosystem resembling well-known vesicular systems including niosomes and liposomes. Cubic phases incorporate lipophobic, amphiphilic and hydrophilic, components through the utilization of a rounded bi-continuous lipid bilayer and water channels. Cubosomes contain lipids such as phytantriol (PHYT) and glycerol monooleate (GMO) which are amphiphilic in nature that are diffused in water and structured in 3-D as a “honeycomb” structure with suitable stabilizer (Poloxamer 407). Cubosomes are generated by mostly two techniques i.e., top-down, bottom-up methods. UV spectrophotometer, X-ray scattering, transmission electron microscopy, and photon correlation spectroscopy are used to characterize and evaluate cubosomes. They are commonly used in the administration of oral, ophthalmic, transdermal, and chemotherapeutic drugs. The liquid crystalline phase and bicontinuous cubic form nanoparticles are thoroughly discussed in this paper. In the current review search criterion used parameters affecting cubosomes bi-continuous lipid bilayer by top-down and bottom-up methods mostly. The sources referred from peer-reviewed recognized journals. Keywords used as filters were cubosomes, amphiphilic lipids, top-down, bottom-up, bicontinuous, GMO, and phytantriol (PHYT). For the purpose of a comprehensive update literature review over a range (1976–2023) has been conducted on the recent developments cubosomes system.

A review on nanotechnology based ophthalmic drug delivery system

The field of ophthalmic drug delivery has witnessed significant advancements through the integration of nanotechnology. Despite having numerous conventional dosage forms employed in the ocular drug delivery system the problem of less bioavailability and less retention time is a significant concern. Along with it there are various barriers also involved that affects the drug permeability, solubility due to the lower residence time of the drug on ocular surface. To overcome these problems the nanotechnology approach can be most suitable. All nanocarriers have emerged as a promising career for precise drug targeting to ocular tissues. Their small size, biocompatibility and surface modification enable improved drug solubility, sustained release and enhanced bioavailability. Moreover nanotechnology facilitates the incorporation of therapeutic agents for various ocular conditions, including glaucoma, macular degeneration and infections. These advancements aim to overcome the challenges and barriers in ocular drug delivery system. This review underscores the immense potential of nanotechnology to revolutionize ophthalmic drug delivery, offering the prospect of more efficient and patient-friendly treatments for ophthalmic disorders.
 Keywords: Ocular drug delivery, Nanotechnology, Nanocarriers, Intraocular pressure, Ophthalmic barriers

Development of Carvedilol Nanoformulation-Loaded Poloxamer-Based In Situ Gel for the Management of Glaucoma.

The objective of the current study was to fabricate a thermosensitive in situ gelling system for the ocular delivery of carvedilol-loaded spanlastics (CRV-SPLs). In situ gel formulations were prepared using poloxamer analogs by a cold method and was further laden with carvedilol-loaded spanlastics to boost the precorneal retention of the drug. The gelation capacity, rheological characteristics, muco-adhesion force and in vitro release of various in situ gel formulations (CS-ISGs) were studied. The optimized formula (F2) obtained at 22% w/v poloxamer 407 and 5% w/v poloxamer 188 was found to have good gelation capacity at body temperature with acceptable muco-adhesion properties, appropriate viscosity at 25 °C that would ease its ocular application, and relatively higher viscosity at 37 °C that promoted prolonged ocular residence of the formulation post eye instillation and displayed a sustained in vitro drug release pattern. Ex vivo transcorneal penetration studies through excised rabbit cornea revealed that F2 elicited a remarkable (p ˂ 0.05) improvement in CRV apparent permeation coefficient (Papp = 6.39 × 10-6 cm/s) compared to plain carvedilol-loaded in situ gel (CRV-ISG; Papp = 2.67 × 10-6 cm/s). Most importantly, in normal rabbits, the optimized formula (F2) resulted in a sustained intraocular pressure reduction and a significant enhancement in the ocular bioavailability of carvedilol, as manifested by a 2-fold increase in the AUC0-6h of CRV in the aqueous humor, compared to plain CRV-ISG formulation. To sum up, the developed thermosensitive in situ gelling system might represent a plausible carrier for ophthalmic drug delivery for better management of glaucoma.

Application of FOCUS-PDCA management mode in standardizing medication of ophthalmic drugs in patients undergoing ambulatory eye surgery

Application of FOCUS-PDCA management mode in standardizing medication of ophthalmic drugs in patients undergoing ambulatory eye surgery

Sustained Release of Voriconazole Using 3D-Crosslinked Hydrogel Rings and Rods for Use in Corneal Drug Delivery.

Corneal disorders and diseases are prevalent in the field of clinical ophthalmology. Fungal keratitis, one of the major factors leading to visual impairment and blindness worldwide, presents significant challenges for traditional topical eye drop treatments. The objective of this study was to create biocompatible 3D-crosslinked hydrogels for drug delivery to the cornea, intending to enhance the bioavailability of ophthalmic drugs. Firstly, a series of flexible and porous hydrogels were synthesized (free-radical polymerization), characterized, and evaluated. The materials were prepared by the free-radical polymerization reaction of 1-vinyl-2-pyrrolidinone (also known as N-vinylpyrrolidone or NVP) and 1,6-hexanediol dimethacrylate (crosslinker) in the presence of polyethylene glycol 1000 (PEG-1000) as the porogen. After the physicochemical characterization of these materials, the chosen hydrogel demonstrated outstanding cytocompatibility in vitro. Subsequently, the selected porous hydrogels could be loaded with voriconazole, an antifungal medication. The procedure was adapted to realize a loading of 175 mg voriconazole per ring, which slightly exceeds the amount of voriconazole that is instilled into the eye via drop therapy (a single eye drop corresponds with approximately 100 mg voriconazole). The voriconazole-loaded rings exhibited a stable zero-order release pattern over the first two hours, which points to a significantly improved bioavailability of the drug. Ex vivo experiments using the established porcine eye model provided confirmation of a 10-fold increase in drug penetration into the cornea (after 2 h of application of the hydrogel ring, 35.8 ± 3.2% of the original dose is retrieved from the cornea, which compares with 3.9 ± 1% of the original dose in the case of eye drop therapy). These innovative hydrogel rods and rings show great potential for improving the bioavailability of ophthalmic drugs, which could potentially lead to reduced hospitalization durations and treatment expenses.

New ophthalmic drug delivery systems

For decades, topical ophthalmic drug administration through the use of eye drops has been the most widely used technique for the treatment of eye diseases. The development of galenic formulation has led to the use and commercialization of new formulations, such as suspensions, emulsions, and ophthalmic ointments that increase residence time in the site of action. Recently, new administration systems have been developed, such as devices and inserts that provide the sustained release of active substance. Some of these systems are already available on the market, whereas others are still undergoing clinical trials, such as promising systems based on nanostructures (nanocapsules, cyclodextrins, nanoemulsions, etc.). Similarly, various formulations and devices have been developed in the field of intravitreal administration, with different implants available on the European market for the treatment of age-related macular degeneration (AMD), diabetic macular edema, or infections that affect the posterior segment. This review includes current developments in ophthalmic topical and intravitreal drug administration routes as well as those under investigation.

DEVELOPMENT AND CHARACTERIZATION OF FLURBIPROFEN LOADED NIOSOMAL IN-SITU GEL FOR OPHTHALMIC DRUG DELIVERY SYSTEM

Niosome are non-ionic surfactant-based liposomes, obtained in the hydration of artificial non-ionic surfactants, without or with addition of cholesterol or additional lipids. The intention of the current study was to organize and evaluate the in-situ niosomal gel loaded with flurbeprofen for the ophthalmic drug delivery system. Flurbeprofen, a nonsteroidal anti- infammatory drug (NSAIDs) is used to relief pain and inflammation. It carries out anti- inflammatory, analgesic and antipyretic activities. Flurbeprofen loaded Niosomes investigate the connection among the non-ionic drug / surfactant ratio with the adding of cholesterol was successfully organized with the thin film hydration way and compare the result of different grade of span used (20, 40 and 60) with the different ratio of cholesterol. Niosomes have been identified by drug entrapment efficiency, drug content, particle size and in-vitro diffusion study. Niosomes prepared using span 60 and cholesterol in the ratio (1:1) f4 showed greater entrapment efficiency (79.2%).

Comprehensive Study of Drug-Induced Pruritus Based on Adverse Drug Reaction Report Database.

Drug-induced pruritus triggers a desire to scratch, thereby diminishing one's quality of life. Certain instances of this phenomenon follow complex mechanisms of action that diverge from histamine-mediated pathways, known contributors to pruritus. However, investigations into the relationship between drugs and pruritus are limited. In this study, data mining techniques were employed to comprehensively analyze the characteristics of drugs linked to pruritus, using the FDA's Adverse Event Reporting System (FAERS) data. Reports linked to pruritus demonstrated noteworthy differences in gender, age, and weight when compared with non-pruritus cases. Among the leading candidates for drugs prompting pruritus were ophthalmic drugs, systemic antibacterials, contrast media, dermatological antifungals, and dermatological preparations. A principal component analysis showed that the second principal component served as an indicator for distinguishing between onsets at mucous membranes or the skin's surface. Additionally, the third principal component functioned as an indicator for categorizing administration methods as either invasive or noninvasive. Furthermore, a hierarchical cluster analysis conducted on these obtained principal components revealed the potential for classifying drugs based on the site of pruritus onset and the method of drug administration. These findings contribute to the development of targeted prevention and treatment strategies for avoiding pruritus in clinical practice.

Development of a Method for Multisensory Stripping Voltammetry in the Analysis of Medical Preparations.

For the effective dosage of newly developed ophthalmic drugs, an assessment of the dynamics of their concentration in lacrimal fluid over time is required. To express the detection and identification of drugs, new methods are needed that must meet numerous requirements, not the least of which are selectivity, speed, the absence of false-negative results, and cost-effectiveness. The possibility of identifying anesthetics (sevoflurane) in lacrimal fluid has been studied using a new electrochemical method of multisensory inversion voltammetry in the electronic tongue and electronic nose format. The measurements were performed on a planar electrode, which is a three-electrode structure. The solution of the test system consisted of 0.05 M KCl, which contained the metal cations Zn2+, Cd2+, Pb2+, Co2+, and Hg2+ at a concentration of 5 × 10-5 M. It is shown that this method is effective for the determination of anesthetics, and the dynamics of changes in their concentration over time are examined. This study aimed to research the behavioral pharmacokinetics in the lacrimal fluid of the opioid drug sevoflurane in pediatric ophthalmology using multisensory stripping voltammetry in patients during strabismus correction surgery. The dynamics of changes in their concentrations over time were examined. After the instillation of the anesthetics in patients, their concentrations in the tear fluid remained unchanged within 10 min. The list of organic substances that can be determined by multisensory stripping voltammetry has been extended. The class of organic substances determined by the method of multisensory inversion voltammetry has been expanded.

Treatments for Ocular Diseases in Pregnancy and Breastfeeding: A Narrative Review.

Pregnancy is a medical condition in which the physiological changes in the maternal body and the potential impact on the developing fetus require a cautious approach in terms of drug administration. Individual treatment, a thorough assessment of the extent of the disease, and a broad knowledge of the therapeutic options and different routes of administration of ophthalmic drugs are essential to ensure the best possible results while minimizing risks. Although there are currently several routes of administration of drugs for the treatment of eye diseases, even with topical administration, there is a certain amount of systemic absorption that must be taken into account. Despite continuous developments and advances in ophthalmic drugs, no updated data are available on their safety profile in these contexts. The purpose of this review is both to summarize the current information on the safety of ophthalmic treatments during pregnancy and lactation and to provide a practical guide to the ophthalmologist for the treatment of eye diseases while minimizing harm to the developing fetus and addressing maternal health needs.

Perspective use of bio-adhesive liquid crystals as ophthalmic drug delivery systems

The success of many drugs in ophthalmic treatments is hindered by their physico-chemical properties and the limited precorneal retention time. Here, lyotropic liquid crystals are proposed as a new ophthalmic drug delivery system. Acyclovir was chosen as model drug for its solubility and its controlled release from cubic phase was achieved. We demonstrated the effortless application of lamellar phase on corneal surface and its ability to convert itself in cubic phase in situ. While the complex viscosity of lamellar phase was affected by temperature (5.1 ± 1.4 kPa·s at 25 °C and 0.12 ± 0.001 Pa·s at 35 °C, respectively), the cubic phase shown no changes in viscosity values and shear thinning behaviour at both temperatures and even in presence of the drug The degradation kinetic of drug-loaded cubic phase was slightly slower than the empty formulation, recording 27.92 ± 1.43% and 33.30 ± 3.11% of weight loss after 8 h. Ex vivo studies conducted on porcine eyeballs and isolated cornea confirmed the instantaneous transition to cubic phase, its ability to resist to gravity force, and forced dripping of simulated tear fluid. Histopathological investigation showed how treated cornea did not report changes in epithelial and stroma structures. In summary, lyotropic liquid crystals could represent an advantageous ophthalmic drug delivery system.

Subconjunctival therapy by cubic liquid crystalline nanoparticles to deliver Triamcinolone acetonide for the management of diabetic Retinopathy: In vivo evidences

The expression of inflammatory markers and vascular endothelial growth factor (VEGF) was found to be upregulated in various posterior ocular disorders, including diabetic retinopathy (DR). Effective delivery of therapeutic agents to the retina poses a significant challenge in ophthalmic drug delivery due to biological ocular barriers. Triamcinolone acetonide (TA) was selected as the model corticosteroid drug targeting cytokines and VEGF in DR. However, despite TA’s low molecular weight and hydrophobicity, which enable it to bypass the conjunctival epithelial barrier, it doesn’t efficiently exert its effect at the target site. Nanocarriers have emerged as a solution to enhance drug delivery to the retina and improve bioavailability. This study aimed to compare the effects of Triamcinolone-loaded cubic liquid crystalline nanoparticles (TA-cubic LCNPs) and TA-Suspension in an experimental DR model administered via the subconjunctival (SCJ) route. The results demonstrated that TA-cubic LCNPs enhanced TA periocular delivery efficacy by reducing inflammatory and VEGF markers through the advanced glycation end products (AGE)/protein kinase C pathway. They were identified as promising nano-carriers, exhibiting potential for targeted delivery to the retina.

Daily disposable contact lenses as a platform for ocular drug delivery of cyclosporine A

Ophthalmic drug delivery is an important area of research that aims to improve the efficacy and convenience of treatment for various eye conditions. There are multiple ways in which drugs can be delivered to the eye, including eye drops, ointments, gels, and inserts. The most prevalent way of administering medication to the eye is through eye drops. They are easy to use and can be self-administered by patients. Nonetheless, eye drops have the disadvantage of being prone to removal by tears, which may result in insufficient drug absorption and reduced effectiveness. Irregular use of active substances can exacerbate the disease, resulting in prolonged treatment with questionable efficacy. Soft contact lenses that serve as ophthalmic drug delivery systems (DDS) can become a viable substitute for traditional treatments. These polymeric lenses can be embedded with various active compounds, some of which are not readily soluble in water or physiological fluids. One such drug is Cyclosporine A (CyA), an immunosuppressant with a high molecular weight and hydrophobic properties, chronically used to treat dry eye syndrome (DES). The article discusses the development of a method for modifying Hilafilcon B contact lenses obtained from drugstores with Cyclosporine A (CyA). The drug was administered to the lenses using an immersion technique, and the process parameters were monitored to control drug release efficiency and profile. The drug release was measured in an Artificial Lacrimal Fluid (ALF) buffer, mimicking tear fluid with a pH of 7.9. The stability of CyA in this buffer was assessed. For the parameters used, the best drug application and release profile was achieved by immersing the contact lenses for 24 hours at 25 °C in a CyA solution containing 20 μg/ml of the active substance and adding 5 mg/ml of Vitamin E.

Dynamic Ex Vivo Porcine Eye Model to Measure Ophthalmic Drug Penetration under Simulated Lacrimal Flow.

Animal models are still used in the research and development of ophthalmic drug products, mainly due to the difficulty in simulating natural physiological conditions with in vitro models, as there is a lack of dynamic protection mechanisms. Therefore, developing alternative ophthalmic models that evaluate drug penetration in the cornea while applying dynamic protection barriers is a contemporary challenge. This study aimed to develop a dynamic ex vivo model using porcine eyes with a simulated lacrimal flow to evaluate the performance of pharmaceutical drug products. A glass donor cell to support a simulated tear flow was designed, optimized, and custom-made. The system was challenged with different formulations (with fluconazole) including excipients with different viscosities (poloxamer 407) and mucoadhesive properties (chitosan). The results were compared to those obtained from a conventional excised cornea model mounted in Franz-type diffusion cells. The dynamic model could differentiate formulations, while the static model did not, overestimating ex vivo drug penetrated amounts. Hence, the dynamic model with simulated tear flow showed to be a simple and promising new alternative method for the drug penetration of ophthalmic formulations that ultimately can reduce the number of animals used in research.

Retrospective evaluation of the incidence of gastrointestinal bleeding in dogs receiving ophthalmic nonsteroidal anti-inflammatory drugs.

To report the incidence of gastrointestinal (GI) bleeding and associated risk factors in a population of dogs receiving ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs). Medical records of dogs prescribed ophthalmic NSAIDs (cases), dogs receiving systemic NSAIDs alone and dogs receiving systemic prednisone alone (controls). Data were collected retrospectively from the medical records of 204 dogs prescribed ophthalmic NSAIDs (diclofenac, ketorolac, or flurbiprofen), which were subdivided based on if they received any concurrent systemic NSAIDs or glucocorticoids, 136 dogs receiving a systemic NSAID (carprofen or meloxicam) alone, and 151 dogs receiving a systemic glucocorticoid (prednisone) alone at a referral hospital from 2015 to 2019. Gastrointestinal bleeds developed in 8/79 (10.1%) of topical NSAID-only cases, 10/136 (7.4%) of systemic NSAID controls, and 14/151 (9.3%) of systemic glucocorticoid controls, with no significant difference between the three groups (p = .6103). There were no significant differences in GI bleed rates between cases treated with ketorolac, diclofenac, or flurbiprofen (p = .160), although severe GI bleeding was only seen in ketorolac-treated dogs. Presence of a known concurrent risk factor for GI bleeding was significantly associated with the development of GI bleed in dogs on ophthalmic NSAIDs (p = .032). Dogs treated with ophthalmic NSAIDs developed GI bleeding at a frequency comparable to dogs receiving systemic NSAIDs or systemic glucocorticoids alone, suggesting that dogs receiving ophthalmic NSAIDs may be at increased risk of GI bleeding.

Impact of Apparatus and Adapter on In vitro Drug Release of Ophthalmic Semisolid Drug Products.

In vitro release testing (IVRT) is a widely used tool for evaluating the quality and performance of drug products. However, standardized sample adaptors or drug release apparatus setups for IVRT studies are still lacking for ophthalmic ointments. The aim of this study was to provide a better understanding of the impact of apparatus and sample adaptor setups on IVRT of ophthalmic ointments. Dexamethasone (DEX), a steroidal ingredient commonly used in ophthalmic drug products, was selected as a model drug. Ointments were prepared by mixing DEX in white petrolatum using a high shear mixer. A novel two-sided adapter was developed to increase the drug release surface area. DEX ointment was placed in one-sided or two-sided release adaptors coupled with 1.2μm polyethersulfone membrane, and the drug release was studied in different USP apparatuses (I, II, and IV). The sample adaptor setups had a minimal impact on cumulative drug release amount per area or release rate while USP IV apparatus with agitated flow enhanced drug release rates. The USP apparatus I with a two-sided semisolid adapter, which uses membranes on both sides, showed dramatically higher cumulative drug release and discriminative release profiles when evaluating ophthalmic formulations. USP apparatuses and sample adaptors are critical considerations for IVRT. Two-sided semisolid adapter provides higher cumulative release, facilitating the discrimination between low drug content ophthalmic ointment formulations with good sensitivity and repeatability without affecting the drug release rate.

Hydrogel Contact Lenses Embedded with Amine-Functionalized Large-Pore Mesoporous Silica Nanoparticles with Extended Hyaluronic Acid Release.

Contact lenses (CLs) have emerged as an effective method for delivering ophthalmic drugs. In this research, we designed hydrogel CLs capable of extended release, utilizing large-pore mesoporous silica nanoparticles (LPMSNs) to deliver hyaluronic acid (HA) for treating dry eye syndrome. LPMSNs were functionalized with amine groups (LPMSN-amine) to enhance HA loading and release capacity. In vitro release studies demonstrated that LPMSN-amine CLs exhibited superior slower HA release than LPMSN-siloxane and standard CLs. Within 120 h, the cumulative amount of HA released from LPMSN-amine CLs reached approximately 275.58 µg, marking a 12.6-fold improvement compared to standard CLs, when loaded from 0.1 wt% HA solutions. Furthermore, LPMSN-amine CLs effectively maintained moisture, mitigating ocular surface dehydration, making them a promising solution for dry eye management. This study successfully developed LPMSN-amine CLs for extended HA release, identifying the optimal functional groups and loading conditions to achieve sustained release.

Ophthalmic Self-Medication Practices and Associated Factors of Using Steroid Eye Drops Among Adult Ophthalmic Patients.

Self-medication is defined as the selection of medicines by individuals to treat self-diagnosed ophthalmic symptoms without consultation of healthcare professionals. Topical steroids can produce severe eye-threatening complications, including the elevation of intraocular pressure (IOP) with possible development of glaucoma and infrequent optic nerve damage. In recent times, many over-the-counter (OTC) ophthalmic preparations are possible without a prescription. There are a lot of concerns about the safety of long-term use of nonprescription ophthalmic drugs, which may lead to a variety of serious ocular complications. To determine the prevalence of self-medication ocular topical steroid practices and associated factors among adult ophthalmic patients attending ophthalmology clinics at King Saud Medical City (KSMC) in Riyadh. A cross-sectional study targeted adults aged 18 or older who had used topical steroids eye drops. The data were collected through interviews, and an online questionnaire was distributed among patients who attended ophthalmology clinics between December 2022 and February 2023. From a total of 308 responses, 92 (29.8%) were using ocular topical, 58 (18.8%) with a prescription, five (1.6%) without a prescription, and 29 (9.4%) with and without a prescription, while 216 (70.1%) did not use it. The frequency of using ocular topical steroids without a prescription among participants was 11 (12%) once and 33 (35%) many times. Additionally, 26 (28.3%) were having complications, mostly eye infections (11, 12.4%), glaucoma (8, 9%), and cataracts (6, 6.7%). The reasons for practicing self-medication ofsteroid eye drops among participants were 14 (15.2%) repeated symptoms, 11 (15.2%) had heard advice from friends, and 11 (15.2%) think they had enough knowledge. The study reported the use of self-medication with steroids in ophthalmology clinics at KSMC, even though detecting a high level of perception and acceptable practices among participants. This practice is mainly due to participants having repeated symptoms and thinking they have enough knowledge. Educating the patients would help in reducing the incidence of self-medication steroid eye drops and its associated complications.

Impact of Latanoprost Antiglaucoma Eyedrops and Their Excipients on Toxicity and Healing Characteristics in the Ex Vivo Eye Irritation Test System.

Corneal epithelial toxicity and delayed healing process have already been attributed to preservatives or some excipients. We study the effects of galenic components in antiglaucoma drugs such as benzalkonium chloride (BAC) or surfactants like macrogolglycerol hydroxystearate 40 (MGHS40) on corneal toxicity in an exvivo system mimicking chronic use. Latanoprost-containing eyedrops are available with and without preservatives on the market. Unpreserved, they are available in different formulations with various excipients like MGHS at different concentrations (0%, 2.5%, and 5%). We studied these in the exvivo bioreactor (EVEIT) on initially injured rabbit corneas. The drugs were applied six times daily for observation periods of 3 or 5days. BAC, 5% MGHS40 solution, and 0.18% hyaluronic acid served as controls. Macroscopic photographic, biochemical methods and corneal integrity quantification were used for evaluation. Toxicity was assessed by measuring wound healing and corneal fluorescein sodium permeability and was confirmed by histology studies. The BAC-preserved formulation resulted in high corneal toxicity, which was expected. Interestingly, the preservative-free (PF) formulation containing 5% MGHS40, carbomer, macrogol4000, and sorbitol showed the highest corneal toxicity, followed by the control formulation with equal MGHS40 concentration, which presented significantly less damage. No toxicity was shown by eyedrops containing 2.5% MGHS40 or salts only. Our study demonstrates a significant corneal toxicity of certain formulations of PF antiglaucoma ophthalmic drugs containing 5% MGHS40 with other excipients compared to other formulations with lower MGHS40 concentrations (2.5% or 0%), or even compared to the solution containing 5% MGHS alone. This suggests a concentration-dependent toxicity of MGHS40, especially in interaction with other excipients, which may increase its epithelial toxicity, and that has to be considered in clinical glaucoma therapy. Further single-component formulation trials are needed to support this interpretation.

Recent Advancement in Ocular Drug Delivery System: A Systematic Review

Recent scientific and technological advancements have made ophthalmology a top priority for the study of therapeutic products, including the creation, preclinical testing, and clinical evaluation of novel medications, medical devices, and drug-medical device combinations. In order to decrease metabolism and elimination and increase residence time in ocular tissues and compartments, sustained-release drug delivery systems such as liposomes, micelles, nano-emulsions, nanoparticles with colloidal structures, and intraocular implants have been developed. Research is also being conducted in the area of cutting-edge medicines, including those based on gene or cell systems, both of which are considered high-risk products because to their intricate structures. Regarding the definition of drug (medicinal product) and recent changes in regulation, this article reviews recent advancements in ophthalmic drug, gene, and cellular delivery systems and related goods as well as breakthroughs in advanced therapeutic medicinal Products.